{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lin HP"],"funding":["NCI NIH HHS"],"pagination":["e82625"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3857776"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(12)"],"pubmed_abstract":["Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a commonly used cell line established from a human lymph node metastatic lesion of prostatic adenocarcinoma. We previously established two relapsed androgen receptor (AR)-rich androgen-independent LNCaP sublines 104-R1 (androgen depleted for 12 months) and 104-R2 cells (androgen depleted for 24 months) from AR-positive androgen-dependent LNCaP 104-S cells. LNCaP 104-R1 and 104-R2 mimics the AR-positive hormone-refractory relapsed tumors in patients receiving androgen ablation therapy. Androgen treatme"],"journal":["PloS one"],"pubmed_title":["Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells."],"pmcid":["PMC3857776"],"funding_grant_id":["P30 CA093373"],"pubmed_authors":["Chen M","Chuu CP","Wang HD","Kung HJ","Hsiao PH","Lin HP","Jiang SS","Hsu JM","Lin CY","Jim WT"],"additional_accession":[]},"is_claimable":false,"name":"Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.","description":"Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a commonly used cell line established from a human lymph node metastatic lesion of prostatic adenocarcinoma. We previously established two relapsed androgen receptor (AR)-rich androgen-independent LNCaP sublines 104-R1 (androgen depleted for 12 months) and 104-R2 cells (androgen depleted for 24 months) from AR-positive androgen-dependent LNCaP 104-S cells. LNCaP 104-R1 and 104-R2 mimics the AR-positive hormone-refractory relapsed tumors in patients receiving androgen ablation therapy. Androgen treatme","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013","modification":"2025-04-04T20:50:57.971Z","creation":"2019-03-26T23:17:17Z"},"accession":"S-EPMC3857776","cross_references":{"pubmed":["24349321"],"doi":["10.1371/journal.pone.0082625"]}}